Related Experiment Video
Updated: Feb 25, 2026
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Treatment of metastatic refractory colorectal cancer following regorafenib failure
Nobumichi Takeuchi1, Kumiko Koike1, Sonomi Yoshida1
1Department of Medical Oncology, Ina Central Hospital, Ina, Nagano 396-8555, Japan.
Abstract:
At present, there is no set strategy for the treatment of patients with colorectal cancer subsequent to the failure of standard treatment, other than the use of regorafenib (RGR) and TAS-102. The best order in which to use these drugs, and their safety and efficacy in combination with other drugs, are currently under investigation. It has been reported that RGR has a resensitizing effect on tumors that have previously failed to respond to anticancer drugs; this makes it a promising salvage therapy for colorectal cancer. The present report describes the results of a retrospective study on 17 patients with metastatic colorectal cancer who received RGR treatment following the failure of standard therapy. Following RGR failure, 71% of the patients were fit for further anticancer treatment, and these patients survived longer than those who did not receive further treatment. Furthermore, this intervention did not shorten the period of best supportive care. As a considerable number patients were fit for further anticancer therapy after RGR treatment, which resulted in prolonged survival without shortening the period of best supportive care, it may be beneficial for future research to focus on finding the optimal time at which to switch from RGR to further anticancer therapy.
Insights
Regorafenib (RGR) shows promise as a salvage therapy for metastatic colorectal cancer. Many patients remain fit for further treatment after RGR failure, leading to longer survival without compromising supportive care.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Standard treatment strategies for metastatic colorectal cancer (mCRC) after initial therapy failure are limited, with regorafenib (RGR) and TAS-102 being primary options.
- RGR is recognized for its potential to resensitize tumors resistant to prior anticancer drugs, positioning it as a key salvage therapy for mCRC.
Purpose of the Study:
- To evaluate the efficacy and patient fitness for subsequent treatments after regorafenib (RGR) failure in metastatic colorectal cancer (mCRC).
- To determine if RGR salvage therapy impacts the duration of best supportive care and overall survival in mCRC patients.
Main Methods:
- Retrospective study involving 17 patients with metastatic colorectal cancer (mCRC).
- Patients received regorafenib (RGR) treatment after failure of standard therapies.
- Analysis of patient fitness for further anticancer treatment and survival outcomes post-RGR failure.
Main Results:
- 71% of patients were fit for further anticancer treatment after regorafenib (RGR) failure.
- Patients who received subsequent anticancer treatment after RGR failure exhibited longer survival periods.
- Regorafenib (RGR) treatment did not shorten the duration of best supportive care.
Conclusions:
- Regorafenib (RGR) is a viable salvage option for metastatic colorectal cancer (mCRC) patients, enabling subsequent treatments and prolonging survival.
- Further research should investigate the optimal timing for transitioning from RGR to other anticancer therapies to maximize patient benefit.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
07:59Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...